JETIR.ORG

ISSN: 2349-5162 | ESTD Year: 2014 | Monthly Issue



# JOURNAL OF EMERGING TECHNOLOGIES AND INNOVATIVE RESEARCH (JETIR)

An International Scholarly Open Access, Peer-reviewed, Refereed Journal

## Gestational Diabetes Mellitus and Macrosomia: A Literature Review

Authors: Ms. Deepti Kukreti, Dr. S.P. Subashini, Dean Galgotias School of Nursing, Ms. Bandhu Sharma, Ms. Hema, (Department of OBG and Medical Surgical Nursing)

GALGOTIAS UNIVERSITY

#### Abstract

*Background:* Fetal macrosomia, defined as a birth weight ≥4,000 g, may affect 12% of newborns of normal women and 15-45% of newborns of women with gestational diabetes mellitus (GDM). The increased risk of macrosomia in GDM is mainly due to the increased insulin resistance of the mother. In GDM, a higher amount of blood glucose passes through the placenta into the fetal circulation. As a result, extra glucose in the fetus is stored as body fat causing macrosomia, which is also called 'large for gestational age'. This paper reviews studies that explored the impact of GDM and fetal macrosomia as well as macrosomia-related complications on birth outcomes and offers an evaluation of maternal and fetal health. Summary: Fetal macrosomia is a common adverse infant outcome of GDM if unrecognized and untreated in time. For the infant, macrosomia increases the risk of shoulder dystocia, clavicle fractures and brachial plexus injury and increases the rate of admissions to the neonatal intensive care unit. For the mother, the risks associated with macrosomia are cesarean delivery, postpartum hemorrhage and vaginal lacerations. Infants of women with GDM are at an increased risk of becoming overweight or obese at a young age (during adolescence) and are more likely to develop type II diabetes later in life. Besides, the findings of several studies that epigenetic alterations of different genes of the fetus of a GDM mother in utero could result in the transgenerational transmission of GDM and type II diabetes are of concern.

Keywords: Diabetes, Gestational, Pregnancy, Foetus, Hyperglycaemia

#### Introduction

Gestational diabetes mellitus (GDM) is defined as glucose intolerance of variable degrees with an onset, or first recognized, during pregnancy. About 15-45% of babies born to diabetic mothers can have macrosomia, which is a 3-fold higher rate when compared to normoglycemic controls. Macrosomia is typically defined as a birth weight above the 90th percentile for gestational age or >4,000 g.

Unlike maternal hyperglycemia, maternal obesity has a strong and independent effect on fetal macrosomia. Gestational age at delivery, maternal pre-pregnancy body mass index (BMI), pregnancy weight gain, maternal height, hypertension and cigarette smoking also have a significant impact. When obese women were compared to normal-weight women, the newborns of obese women had more than double the risk of macrosomia compared to those of women with normal weight.

Data from the Diabetes in Early Pregnancy Study indicate that fetal birth weight correlates best with secondand third-trimester postprandial blood sugar levels and not with fasting or mean glucose levels. When postprandial glucose values average 120 mg/dl or less, approximately 20% of infants can be expected to be macrosomic, and if the glucose values are as high as 160 mg/dl, the rate of macrosomia can reach up to 35%. Macrosomic foetuses in diabetic pregnancies develop a unique pattern of overgrowth, involving the central deposition of subcutaneous fat in the abdominal and interscapular areas.

Macrosomia is associated with excessive rates of neonatal morbidity. Macrosomic neonates have 5-fold higher rates of severe hypoglycemia and a doubled increase in neonatal jaundice in comparison with the infants of mothers without diabetes.

In addition, there appears to be a role for excessive fetal insulin levels in causing accelerated fetal growth. In a study which compared umbilical cord sera in infants of diabetic mothers and controls, the heavier, fatter babies from diabetic pregnancies were also hyperinsulinemia

## Pathophysiology of GDM

The exact mechanisms behind GDM still remain unclear. The following maternal and fetal-placental factors are interrelated and act in an integrated manner in the development of insulin resistance and GDM.

## The Role of the Fetal-Placental Unit in the Development of GDM

During pregnancy, as gestational age progresses, the size of the placenta increases. There is a rise in the levels of pregnancy-associated hormones like estrogen, progesterone, cortisol and placental lactogen in the maternal circulation accompanied by an increasing insulin resistance. This usually begins between 20 and 24 weeks of gestation. As the mother goes through parturition and delivers the fetus, the placental hormone production stops, and so does the illness of GDM, which strongly suggests that these hormones cause GDM. Human placental lactogen raises approximately 10-fold in the second half of the pregnancy. It stimulates lipolysis, which leads to an increase in free fatty acids in order to provide a different fuel to the mother and to conserve glucose and amino acids for the fetus. In turn, the increase in free fatty acid levels directly interferes with the insulin-directed entry of glucose into cells. Therefore, human placental lactogen is considered as a potent antagonist of insulin action during pregnancy.

## The Role of Adipose Tissue in the Development of GDM

Adipose tissue produces adipocytokines, including leptin, adiponectin, tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) and interleukin-6, as well as the newly discovered resistin, visfatin and apelin. The roles of adipocytokines and elevated lipid concentrations in pregnancy have also been associated with the changes in insulin sensitivity in nonpregnant women as well as in pregnant women. Evidence suggests that one or more of these adipokines might impair insulin signalling and cause insulin resistance. Specifically, TNF-α has a potential role in decreasing insulin sensitivity.

## **Macrosomia-Related Complications**

#### **Maternal Complications**

If the baby is atypically large, vaginal birth will be more complicated. There is a risk of prolonged labor in which the fetus might be stuck in the birth canal, instrumental delivery (with forceps or vacuum) may be needed, and even unplanned or emergency cesarean section may be necessary. During birth, there is a greater risk of laceration and tear of the vaginal tissue than when the baby is of normal size, and the muscle between the vagina and the anus might tear (perineal tear).

There is also a high chance of uterine atony. The uterus muscle may not properly contract, resulting in heavy bleeding and postpartum hemorrhage. The risk of postpartum bleeding and genital tract injury was about 3-5 times higher in macrosomic deliveries [16]. Besides, if the mother has had a previous cesarean section, there is a higher chance of uterus tear along the scar line of the previous surgery.

## **Fetal Complications**

## 1. Immediate Complications

*Premature Birth.* Due to early induction of labor before 39 weeks of gestation and/or premature rupture of membranes, there is a risk of preterm delivery. Although all the necessary precautions are undertaken prior to induction of early labor, newborns are still under the risk of complications associated with prematurity, including difficulties in respiration and feeding, infection, jaundice, neonatal intensive care unit admission and perinatal death.

Shoulder Dystocia and Erb's Palsy. One of the most serious complications of vaginal delivery in macrosomic babies is shoulder dystocia which is associated with birth trauma. Newborns with a birth weight of 4,500 g or more carry a 6 times higher risk of birth trauma [17], and the risk of brachial plexus injury is approximately 20 times higher when the birth weight is above 4,500 g.

Hypoglycemia at Birth. One of the most common metabolic disorders of the neonate of a GDM mother is hypoglycemia. It occurs due to the hyperinsulinemia of the fetus in response to the maternal hyperglycemia in utero. Hypoglycemia can lead to more serious complications like severe central nervous system and cardiopulmonary disturbances. Major long-term sequelae include neurologic damage resulting in mental retardation, recurrent seizure activity, developmental delay and personality disorders.

*Neonatal Jaundice*. Factors which may account for jaundice are prematurity, impaired hepatic conjugation of bilirubin and increased enterohepatic circulation of bilirubin resulting from poor feeding. In macrosomia, neonates have a high oxygen demand causing increased erythropoiesis and, ultimately, polycythemia. Therefore, when these cells break down, bilirubin (a byproduct of red blood cells) increases resulting in neonatal jaundice.

Congenital Anomalies. Heart defects and neural tube defects, such as spina bifida, are the most common types of birth defects. The high blood sugar level of women with GDM can damage the developing organs of the fetus, leading to congenital anomalies.

Later Complications

Childhood Obesity and Metabolic Syndrome. Many studies suggest that one of the reasons of childhood obesity is GDM. There has been evidence of fetal programming of later adiposity amongst offspring exposed

to existing diabetes in utero. The offspring of Pima Indian women with preexisting type II diabetes and GDM were larger for gestational age at birth and, after approximately 5 years of age, were heavier than the offspring of prediabetic or nondiabetic women. The Exploring Perinatal Outcomes among Children (EPOCH) study found that exposure to maternal GDM was associated with a higher BMI, a greater waist circumference, more visceral and subcutaneous adipose tissue and a more centralized fat distribution pattern in 6- to 13-year-old multiethnic youth. Moreover, youth exposed to maternal GDM in utero had an overall higher average BMI growth from 27 months through 13 years of age and a higher BMI growth velocity starting at age 10-13 years. These findings suggest that the long-term effects of in utero GDM exposure are not always evident in early childhood, but rather emerge during puberty, another sensitive period for the development of obesity. Offspring of diabetic mothers is also susceptible to the onset of metabolic syndromes such as increased blood pressure, hyperglycemia, obesity and abnormal cholesterol levels that occur together and increase the risk of heart disease, stroke and diabetes.

### **Management of Macrosomia**

There are various recommendations for the management of macrosomia varying from expectant management and elective induction of labor before term to elective caesarean section for an estimated fetal weight of  $\geq 4,250$  g or >4,500 g depending on the study.

Studies have shown that the chance of vaginal delivery is higher when spontaneous labor occurs than when labor is inducted. However, waiting for spontaneous labor to begin is an option limited by gestational age. As the gestational age exceeds 41 weeks of gestation, maternal morbidity and perinatal morbidity and mortality increase. Hence, timely action to induct delivery is needed.

#### **Early Induction of Labor**

Given that after 37 weeks of gestation the fetus continues to grow at a rate of 230 g/week, elective induction of labor before or near term has been proposed to prevent macrosomia and its complications. However, there are two factors necessary for the induction of labor: the first is fetal lung maturation. Fetuses with a diabetic mother have been shown to have delayed lung maturity. Normally, the pulmonary maturation takes place at a mean gestational age of 34-35 weeks. By 37 weeks, 99% of fetuses are matured. However, in the fetus of a diabetic mother, the lung may not be mature until 38.5 weeks. The second important point is that the patient who is going to undergo induction must have a ripe cervix with a Bishop score of ≥6; otherwise, there is an increased chance of failure of induction, which ultimately leads to a cesarean section. In one study, the outcomes of suspected macrosomic infants of mothers who had expectant management of pregnancy versus elective induction of labor were compared. The rate of cesarean sections was found to be very high (57 vs. 31%) in those who were assigned to the electively inducted group. In some studies, elective induction of labor for macrosomia was found to increase the rate of cesarean delivery without improvement in perinatal outcomes.

#### **Elective Caesarean Section**

Many studies suggest offering a cesarean section to patients who are suspected of expecting a macrosomic infant, especially to those with GDM, insulin-dependent diabetes and a previous high-birth-weight infant, so as to prevent maternal and fetal birth trauma. Unfortunately, measures to calculate the weight of the fetus are inaccurate. In one study, it was claimed that, in a general population, it is unreasonable to perform an elective caesarean section to prevent brachial plexopathy.

#### **Management of the Neonate**

Large-for-gestational-age neonates do not only include post term infants, but also term or even preterm infants. This should be kept in mind as the management and the main concerns in treatment could differ. A strictly regulated maternal blood sugar level decreases the perinatal adverse outcomes.

Neonates with a diabetic mother should undergo a full physical examination from head to toe, congenital anomalies (congenital heart defects, tracheoesophageal fistula and central nervous system abnormalities) and birth trauma being of more concern. They should receive intensive observation and care and should be evaluated for hypoglycemia, polycythemia, hyperbilirubinemia and electrolyte abnormalities.

The blood glucose level should be examined within 1 h of life, then every hour for the next 6-8 h and then as needed. Oral feeding, ideally breast feeding, is recommended as soon as possible, and if oral feeding is insufficient, an intravenous infusion of glucose should be started.

#### REFERENCES

- 1. Ehrenberg HM, Mercer BM, Catalano PM: The influence of obesity and diabetes on the prevalence of macrosomia. Am J Obstet Gynecol 2004;191:964-968.
- 2. Yogev Y, Langer O: Pregnancy outcome in obese and morbidly obese gestational diabetic women. Eur J Obstet Gynecol Reprod Biol 2008;137:21-26.
- 3. Jovanovic-Peterson L, Peterson CM, Reed GF, Metzger BE, Mills JL, Knopp RH, et al: Maternal postprandial glucose levels and infant birth weight: the Diabetes in Early Pregnancy Study. The National Institute of Child Health and Human Development-Diabetes in Early Pregnancy Study. Am J Obstet Gynecol 1991;164:103-111.
- 4. McFarland MB, Trylovich CG, Langer O: Anthropometric differences in macrosomic infants of diabetic and nondiabetic mothers. J Matern Fetal Med 1998;7:292-295.
- 5. Athukorala C, Crowther CA, Willson K: Women with gestational diabetes mellitus in the ACHOIS trial: risk factors for shoulder dystocia. Aust NZ J Obstet Gynaecol 2007;47:37-41.